Stifel Raises Danaher (DHR) Price Target to $260
Key Points
- Stifel reiterated its Buy rating on Danaher Corporation on October 22, 2026, and moved its price target up to $260 from $220.
- Stifel's $260 price target implies 11.46% upside from Danaher Corporation's ($DHR) current $233.27 share price.
- Danaher shares recently traded around $233.27, up about 1.6% from their event-day close of $229.54.
- Institutional funds including Capital International Investors and Robeco Institutional Asset Management adjusted their positions in the healthcare stock.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
On October 22, 2026, Stifel reaffirmed its Buy rating on Danaher Corporation (NYSE:DHR) and lifted its price target to $260 from $220. The research note outlines a more optimistic outlook for the healthcare equipment provider as broader market conditions evolve. Stifel's updated price target sits above the stock's recent trading levels.
DHR
Danaher Corporation
Stifel's Call on Danaher Corporation
In its research note on October 22, 2026, Stifel maintained its Buy rating on the company while substantially increasing its price target from the previous level of $220.00 to $260.00. The forward-looking call signals increased confidence in the firm's business segments spanning biotechnology, life sciences, and diagnostics.
Other Institutional Activity in Danaher Corporation
Large institutional investors have continued to adjust their stakes in Danaher. Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3,558,962,060 after a 10.6% increase. On the other hand, Robeco Institutional Asset Management B.V. reduced its holdings by 330,568 shares, ending with 84,148 shares worth about $18,642,989 following a 79.7% decrease.
Danaher Corporation Stock Up 4.0%
Danaher shares recently traded around $233.27 as of October 22, 2026, up about 1.6% from their closing price of $229.54 on the day of the analyst update. The stock is currently trading above both its 50-day moving average of $215.12 and its 200-day moving average of $201.26. The company carries a market capitalization of roughly $164.4 billion.
$DHR price target
Danaher Corporation daily closes and this analyst's $260 target. Not advice.
Recent Earnings
For the trailing twelve months, Danaher reported $25.11 billion in revenue and earnings of $6.04 per share. The company posted a net profit margin of 15.9% and a return on equity of 7.6%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share, which translates to a dividend yield of 0.71% based on a dividend payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Company insiders have executed transactions in recent months. Chief Executive Officer Rainer M Blair disposed of 58,255 shares worth $12,736,095 on August 21, 2026. Earlier, on May 1, 2026, Director Alan G Spoon sold 1,358 shares at a price of $174.67 for a total value of $237,207.
Analysts Set New Price Targets
Wall Street firms updated their views alongside Stifel on October 22, 2026. Barclays maintained its Overweight rating and raised its target from $255.00 to $260.00. JP Morgan maintained an Overweight rating and lifted its target from $250.00 to $270.00. TD Cowen maintained a Buy rating and raised its target from $255.00 to $270.00. Baird maintained an Outperform rating while moving its target from $246.00 to $254.00. Overall, the stock carries a consensus recommendation of strong buy across 22 analyst opinions.
About Danaher Corporation
Danaher Corporation operates as a science and technology innovator that designs and manufactures medical, industrial, and research products. The company focuses on core segments including biotechnology, life sciences, and diagnostics, providing critical tools and consumables to laboratories and healthcare providers worldwide.
Bottom Line
Stifel's higher price target reflects growing optimism among analysts covering the healthcare giant. Investors will monitor upcoming earnings reports and institutional filing updates to see if the positive sentiment translates into sustained momentum for the share price.
Related Filing Alerts
Source: Stifel's rating change on $DHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts